Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic...

Area of Science:

• Neuroimmunology
• Vaccinology
• Autoimmune Disease Research

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system (CNS).
• Myelin proteolipid protein (PLP) is a key autoantigen implicated in MS pathogenesis.
• Developing effective therapeutic strategies for MS remains a significant challenge.

Purpose of the Study:

• To investigate the efficacy of a recombinant vaccinia virus encoding PLP (VVplp) in a mouse model of experimental autoimmune encephalomyelitis (EAE).
• To evaluate the impact of VVplp vaccination on disease severity, clinical relapses, and CNS pathology.
• To explore the underlying immunological mechanisms, including T cell responses and cytokine profiles, associated with VVplp vaccination.

Main Methods:

• Induction of EAE in mice using the encephalitogenic PLP139-151 peptide.
• Vaccination of mice with VVplp, control vaccinia virus, or mock vaccine.
• Clinical scoring of disease severity and relapses.
• Histopathological analysis of CNS tissue for inflammation and demyelination.
• Assessment of T cell proliferation and delayed-type hypersensitivity (DTH) responses in vitro and in vivo.
• Measurement of IL-4 levels during remission.

Main Results:

• VVplp-vaccinated mice exhibited a more severe acute EAE attack but significantly reduced relapses and overall disease burden compared to controls.
• Histopathology revealed markedly reduced CNS inflammation and demyelination in VVplp-vaccinated mice during remission, with inflammation primarily confined to the meninges.
• VVplp vaccination led to decreased T cell proliferation and DTH responses to PLP139-151, correlating with sustained remission.
• Elevated IL-4 levels were observed during the remission phase in VVplp-vaccinated mice.

Conclusions:

• VVplp vaccination can induce a state of long-term remission in a PLP-induced EAE model.
• This remission is associated with reduced T cell responsiveness to the encephalitogenic PLP peptide.
• The findings suggest a potential therapeutic strategy for MS by modulating T cell reactivity through viral vector-based vaccination.